Combined pharmaceutical formulation with controlled-release comprising Dihydropyridine calcium channel blockers and HMG-CoA reductase inhibitors
Details for Australian Patent Application No. 2007288544 (hide)
International Classifications
Event Publications
9 April 2009 PCT application entered the National Phase
PCT publication WO2008/023958 Priority application(s): WO2008/023958
30 April 2009 Amendment Made
The nature of the amendment is as shown in the statement(s) filed 16 Mar 2009
17 June 2010 Alteration of Name
The name of the applicant has been altered to Hanall BioPharma Co., Ltd.
22 September 2011 Application Accepted
Published as AU-B-2007288544
19 January 2012 Standard Patent Sealed
Legal
The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.
Next and Previous Patents/Applications
IP Reporting Samples
Customised IP Reporting
IP Insider for IP Professionals
IP Monitor Professional
- Editable Word format reports
- For IP Professionals
- Multiuser